News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Opko Health, Inc. Surpasses 50% Enrollment in Second Phase 3 Trial of Rayaldy™


8/15/2013 11:07:43 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MIAMI--(BUSINESS WIRE)--OPKO Health, Inc. (NYSE: OPK), has surpassed 50% enrollment in the second phase 3 trial of Rayaldy™ to treat patients with secondary hyperparathyroidism (SHPT), stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency. This trial is the second of two identical randomized, double-blind, placebo controlled, multi-site studies intended to establish the safety and efficacy of Rayaldy™ as a new treatment for SHPT in the targeted population. The endpoints of both studies, which are being conducted in parallel, include vitamin D status and changes in serum calcium, serum phosphorus and plasma intact parathyroid hormone (PTH).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES